LGALS3 and peripheral nerve injury: Conclusion: Our data demonstrated that MCP could effectively inhibit gal3 expression and SNL-induced neuroinflammation and neuropathic pain in rats, and suggest its candidacy as a new target for clinical management of peripheral nerve injury-induced neuropathic pain.